BerGenBio ASA: Grant of share options
Bergen, Norway, 8 December 2023 – BerGenBio ASA (the “Company”) (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announce that the Board of Directors has granted options to employees. The annual general meeting in the Company on 22 May 2023 approved the share option program and authorised the board of directors of the Company to issue up to 129,090,000 share options to the Company’s employees as part of a long-term incentive plan. Options granted under the share option program will